Novo Nordisk shares shoot up amid promising results for anti-obesity pill | Pharmaceuticals industry
The value of the drug producer Novo Nordisk has increased by more than 6.5 billion after showing that the new anti-bezity pill of the research against the US rival Eli Lilly, as wegovy Jab competed against the market to be treated as a tablet.
The stock at the Denmark company climbed more than 4.5% on Thursday morning and hopes that GLP-1 drugs could return to Lilly and cheaper generic versions. As sales slowed down, stocks fell approximately 60% last year.
Novo Nordisk Say on Thursday Wegovy’s loss of “important weight önce in a clinical attempt of the pill version once a day is that one out of all three participants loses 20% or more weight. Side effects were similar to the injectable version.
It is the first oral GLP-1 medication submitted to the US regulator, food and drug administration, and the company awaits a decision whether the FDA will approve for use by the end of the year. Novo Nordisk’in US sites have already begun production.
Danish company Eli Lilly’s daily weight loss pill called Orkorglpron. On Tuesday, the US drug producer said that one of the five people lost 20% or more weight for 72 weeks at the hearing of 3,127 adults. Patients lost 12.4% of the average body weight at the highest dose.
In 2018, Japan developed Osforglpron with a compound obtained from Chugai Pharmaceutical. Eli Lilly plans to send the pill to the regulator later this year, and some analysts say FDA can be watched quickly. Jeferveries analysts estimate $ 25 billion peak sales per year for Oborglpron.
Matthew Weston, an UBS analyst, said that Novo has seen “open leadership için for the oral obesity pill,“ The orientalpron still offers a threat to be a more scalable product and therefore a potentially discounted price.
Although the anti-obesity jabs that mimic a bowel hormone called GLP-1 are extremely popular, especially Eli Lilly is very expensive after the last price increase up to 170% in England. NHS has limited its usability to people with high clinical need.
It is easier to produce, storage, distribute and implement pill versions and are expected to be cheaper, and millions of people open a way to lose weight at a time when obesity increases worldwide.
The shares of GLP-1 drug producers, pharmaceutical companies that do not make these weight loss drugs have greatly performed better. On Tuesday, an investment platform Ethoro increased a basket of Novo Nordisk, Eli Lilly, Sanofi, Teva and Hikma shares by 106% in the last five years, while Johnson & Johnson, GSK, Abbvie and Bayer only increased by 27%. Eli Lilly shares increased by about 395% during the period, while Novo Nordisk is still 69% ahead despite the sharp decrease last year.
